Emerging methods in chemoproteomics with relevance to drug discovery

Methods in Molecular Biology

Volumn 1513, Issue , 2017, Pages 11-22

  Nguyen, Chuong ^a   West, Graham M ^a   Geoghegan, Kieran F ^a  

^a PFIZER INC   (United States)

Author keywords

CETSA; Chemoproteomics; DARTS; Kinobeads; LiP SRM; PROTAC; Proteomics; SPROX

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; ANTINEOPLASTIC AGENT; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

CELL ASSAY; CELLULAR THERMAL SHIFT ASSAY; CHEMICAL STRUCTURE; CHIMERA; DRUG DESIGN; DRUG INDUSTRY; HUMAN; OXIDATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEOMICS; ANTAGONISTS AND INHIBITORS; BIOASSAY; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION; GENETICS; K-562 CELL LINE; METABOLISM; OXIDATION REDUCTION REACTION; PROCEDURES; PROTEIN DENATURATION; THERMODYNAMICS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; DRUG DISCOVERY; GENE EXPRESSION; HUMANS; K562 CELLS; NEOPLASM PROTEINS; OXIDATION-REDUCTION; PROTEIN DENATURATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STABILITY; PROTEOMICS; THERMODYNAMICS;

EID: 84994353647     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-6539-7_2     Document Type: Chapter

References (39)

1. O’Farrell PH (2008) The pre-omics era: the early days of two-dimensional gels. Proteomics 8:4842-4852
2. Henzel W, Watanabe C, Stults J (2003) Protein identification: the origins of peptide mass fingerprinting. J Am Soc Mass Spectrom 14:931-942
3. Patterson SD, Aebersold RH (2003) Proteomics: the first decade and beyond. Nat Genet 33:311-323
4. Gillette MA, Carr SA (2013) Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods 10:28-34
5. Cohen J (2001) The proteomics payoff. Technol Rev 104:54-60
6. Ito T, Ando H, Suzuki T et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350
7. Geoghegan KF, Johnson DS (2010) Chemical proteomic technologies for drug target identification. Annu Rep Med Chem 45:345-360
8. Niphakis MJ, Cravatt BF (2014) Enzyme inhibitor discovery by activity-based protein profiling. Annu Rev Biochem 83:341-377
9. Cravatt BF, Wright AT, Kozarich JW (2008) Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu Rev Biochem 77:383-414
10. Molina DM, Jafari R, Ignatushchenko M et al (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341:84-87
11. Savitski MM, Reinhard FBM, Franken H et al (2014) Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346:55
12. Adhikari J, West GM, Fitzgerald MC (2015) Global analysis of protein folding thermodynamics for disease state characterization. J Proteome Res 14:2287-2297
13. Strickland EC, Geer MA, Tran DT et al (2013) Thermodynamic analysis of protein-ligand binding interactions in complex biological mixtures using the stability of proteins from rates of oxidation. Nat Protoc 8:148-161
14. West GM, Tang L, Fitzgerald MC (2008) Thermodynamic analysis of protein stability and ligand binding using a chemical modification-and mass spectrometry-based strategy. Anal Chem 80:4175-4185
15. Lomenick B, Olsen RW, Huang J (2011) Identification of direct protein targets of small molecules. ACS Chem Biol 6:34-46
16. Lomenick B, Hao R, Jonai N et al (2009) Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A 106:21984-21989
17. Liu PF, Kihara D, Park C (2011) Energeticsbased discovery of protein-ligand interactions on a proteomic scale. J Mol Biol 408:147-162
18. West GM, Tucker CL, Xu T et al (2010) Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements. Proc Natl Acad Sci U S A 107:9078-9082
19. Zhu MM, Rempel DL, Du Z, Gross ML (2003) Quantification of protein-ligand interactions by mass spectrometry, titration, and H/D exchange: PLIMSTEX. J Am Chem Soc 125:5252-5253
20. Tang L, Sundaram S, Zhang J et al (2013) Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry. MAbs 5:114-125
21. Liyanage R, Devarapalli N, Puckett LM (2009) Comparison of two ESI MS based H/D exchange methods for extracting protein folding energies. Int J Mass Spectrom 287: 96-104
22. Cohen P (2002) Protein kinases—the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309-315
23. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745
24. Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132
25. Patricelli MP, Szardenings AK, Liyanage M et al (2007) Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46:350-358
26. Bantscheff M, Eberhard D, Abraham Y et al (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035-1044
27. Ross PL, Huang YN, Marchese JN et al (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154-1169
28. Médard G, Pachl F, Ruprecht B et al (2015) Optimized chemical proteomics assay for kinase inhibitor profiling. J Proteome Res 14:1574-1586
29. Becher I, Savitski MM, Savitski MF et al (2013) Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP. ACS Chem Biol 8:599-607
30. Grossmann J, Roschitzki B, Panse C et al (2010) Implementation and evaluation of relative and absolute quantification in shotgun proteomics with label-free methods. J Proteomics 73:1740-1746
31. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367-1372
32. Lemeer S, Zörgiebel C, Ruprecht B et al (2013) Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J Proteome Res 12:1723-1731
33. Cohen P, Tcherpakov M (2010) Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143:686-693
34. Krönke J, Fink EC, Hollenbach PW et al (2015) Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523:183-188
35. Zhou P, Bogacki R, McReynolds L, Howley PM (2000) Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 6:751-756
36. Carmony KC, Kim KB (2012) PROTACinduced proteolytic targeting. Methods Mol Biol 832:627-638
37. Sakamoto KM (2010) Protacs for treatment of cancer. Pediatr Res 67:505-508
38. Bondeson DP, Mares A, Smith IED et al (2015) Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol 11:611-617
39. Lu J, Qian Y, Altieri M et al (2015) Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 22:755-763